JPH0338248B2 - - Google Patents
Info
- Publication number
- JPH0338248B2 JPH0338248B2 JP57186884A JP18688482A JPH0338248B2 JP H0338248 B2 JPH0338248 B2 JP H0338248B2 JP 57186884 A JP57186884 A JP 57186884A JP 18688482 A JP18688482 A JP 18688482A JP H0338248 B2 JPH0338248 B2 JP H0338248B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- parts
- nifedipine
- tablets
- starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 38
- 229960001597 nifedipine Drugs 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 23
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 21
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 21
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 21
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 21
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 21
- 229920002472 Starch Polymers 0.000 claims description 19
- 239000008107 starch Substances 0.000 claims description 19
- 235000019698 starch Nutrition 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- NHOFYNWYKKGKKX-UHFFFAOYSA-N 1-(4-nitrophenyl)-2h-pyridine Chemical class C1=CC([N+](=O)[O-])=CC=C1N1C=CC=CC1 NHOFYNWYKKGKKX-UHFFFAOYSA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 230000002745 absorbent Effects 0.000 claims description 4
- 239000002250 absorbent Substances 0.000 claims description 4
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 239000007940 sugar coated tablet Substances 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- 239000000243 solution Substances 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 9
- 229960000715 nimodipine Drugs 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000004408 titanium dioxide Substances 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- -1 -isopropyl ester Chemical class 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920003085 Kollidon® CL Polymers 0.000 description 2
- 229920003072 Plasdone™ povidone Polymers 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE31428533 | 1981-10-29 | ||
| DE19813142853 DE3142853A1 (de) | 1981-10-29 | 1981-10-29 | Feste arzneizubereitungen mit nifedipin und verfahren zu ihrer herstellung |
| DE32053991 | 1982-02-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5883617A JPS5883617A (ja) | 1983-05-19 |
| JPH0338248B2 true JPH0338248B2 (de) | 1991-06-10 |
Family
ID=6145080
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57186884A Granted JPS5883617A (ja) | 1981-10-29 | 1982-10-26 | ジヒドロピリジンを含有する固体の迅速放出性薬剤調製物及びその製造方法 |
| JP61223924A Pending JPS62228017A (ja) | 1981-10-29 | 1986-09-24 | ジヒドロピリジンを含有する固体の迅速放出性薬剤調製物の製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61223924A Pending JPS62228017A (ja) | 1981-10-29 | 1986-09-24 | ジヒドロピリジンを含有する固体の迅速放出性薬剤調製物の製造方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (2) | JPS5883617A (de) |
| DE (1) | DE3142853A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3142853A1 (de) * | 1981-10-29 | 1983-05-11 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitungen mit nifedipin und verfahren zu ihrer herstellung |
| JPS59101423A (ja) * | 1982-12-02 | 1984-06-12 | Takada Seiyaku Kk | 新規なニフエジピン固形製剤 |
| DE3318649A1 (de) * | 1983-05-21 | 1984-11-22 | Bayer Ag, 5090 Leverkusen | Zweiphasenformulierung |
| US4794111A (en) * | 1984-05-23 | 1988-12-27 | Bayer Aktiengesellschaft | Dihydropyridine preparations containing β-blockers |
| DE3424553A1 (de) * | 1984-07-04 | 1986-01-09 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung |
| DE3433239A1 (de) * | 1984-09-11 | 1986-03-20 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung |
| US5543099A (en) * | 1994-09-29 | 1996-08-06 | Hallmark Pharmaceutical, Inc. | Process to manufacture micronized nifedipine granules for sustained release medicaments |
| DE19515972A1 (de) * | 1995-05-02 | 1996-11-07 | Bayer Ag | Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung |
| TW527195B (en) | 1997-10-09 | 2003-04-11 | Ssp Co Ltd | Fast-soluble solid pharmaceutical combinations |
| EP1813274B1 (de) * | 2004-10-06 | 2009-12-16 | Eisai R&D Management Co., Ltd. | Medizinische zusammensetzung, verfahren zu ihrer herstellung und verfahren zur stabilisierung einer dihydropyridin-verbindung in einer medizinischen zusammensetzung |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2200778B2 (de) * | 1971-01-13 | 1974-04-18 | Sandoz Ag, Basel (Schweiz) | Verwendung von hochmolekularem, unlöslichem, quervernetztem Polyvinylpyrrolidon als Sprengmittel in festen Arzneiformen |
| JPS5283919A (en) * | 1976-01-01 | 1977-07-13 | Sandoz Ag | Pharmaceutical tablet |
| FR2391882A1 (fr) * | 1977-05-25 | 1978-12-22 | Ducellier & Cie | Balai d'essuie-glace pour vehicules automobiles |
| GB1579818A (en) * | 1977-06-07 | 1980-11-26 | Yamanouchi Pharma Co Ltd | Nifedipine-containing solid preparation composition |
| JPS542316A (en) * | 1977-06-07 | 1979-01-09 | Yamanouchi Pharmaceut Co Ltd | Solid pharmaceutical composition containing nifedipene |
| JPS5420127A (en) * | 1977-07-14 | 1979-02-15 | Yamanouchi Pharmaceut Co Ltd | Solid nifedipine preparaton |
| DE2815578C2 (de) * | 1978-04-11 | 1986-01-16 | Bayer Ag, 5090 Leverkusen | Neue pharmazeutische Verwendung von Nimodipin |
| DE3142853A1 (de) * | 1981-10-29 | 1983-05-11 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitungen mit nifedipin und verfahren zu ihrer herstellung |
-
1981
- 1981-10-29 DE DE19813142853 patent/DE3142853A1/de active Granted
-
1982
- 1982-10-26 JP JP57186884A patent/JPS5883617A/ja active Granted
-
1986
- 1986-09-24 JP JP61223924A patent/JPS62228017A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE3142853C2 (de) | 1989-06-29 |
| JPS62228017A (ja) | 1987-10-06 |
| DE3142853A1 (de) | 1983-05-11 |
| JPS5883617A (ja) | 1983-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4981683A (en) | Solid, rapidly released medicament preparations containing dihydropyridines, and processes for their preparation | |
| US5015479A (en) | Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine | |
| US4673564A (en) | Sustained release pharmaceutical composition of solid medical material | |
| EP0717986B1 (de) | Rotogranulat und Beschichtung von Acetaminophen, Pseudoephedrin, Chlorpheniramin und, gegebenenfalls, Dextromethorphan | |
| US7976869B2 (en) | Fenofibrate tablets | |
| JP2763879B2 (ja) | 徐放性カプセルもしくは錠剤製剤及びその調製方法 | |
| JP2003504324A (ja) | 味がマスクされ、活性成分を即時放出する、被覆された顆粒の製造方法 | |
| JP2001518490A (ja) | 味遮蔽された製剤 | |
| WO1999033467A1 (en) | Method and composition of an oral preparation of itraconazole | |
| JPH05200099A (ja) | 活性成分を含有する予め成形された微小粒子より製造される機械的に安定でかつ容易に分解し得る錠剤 | |
| CA2874779C (en) | Pharmaceutical composition of entecavir and process of manufacturing | |
| KR920006908B1 (ko) | 디히드로피리딘을 함유하는 고상 약제의 제조 방법 | |
| WO1994005262A1 (en) | Sustained release matrix composition | |
| JPH0338248B2 (de) | ||
| US20020076444A1 (en) | Novel method for obtaining microspheres and resulting products | |
| JP2000256195A (ja) | ニフェジピン小丸薬およびニフェジピン小丸薬の調製方法 | |
| EP0410422B1 (de) | Stark absorbierbares Arzneimittel | |
| JPH10152440A (ja) | 活性物質としてニフェジピンを含有する経口投与用調節放出医薬組成物 | |
| US8062664B2 (en) | Process for preparing formulations of lipid-regulating drugs | |
| JPH029007B2 (de) | ||
| USRE33963E (en) | Solid rapidly released medicament preparations containing dihydropyridines, and processes for their preparation | |
| JP2003116966A (ja) | 直接錠剤化用調合物および補助剤の調合方法 | |
| CA2118133C (en) | Aminoguanidine spray drying process | |
| JP2000516601A (ja) | 水溶性化合物及びセルロースを含有する粒状物 | |
| KR880001558B1 (ko) | 디하이드로피리딘을 함유하는 속방출성 고형약제의 제조방법 |